345 related articles for article (PubMed ID: 32898244)
41. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
42. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
43. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
44. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
[TBL] [Abstract][Full Text] [Related]
45. Pomalidomide therapy for myeloma.
Schey S; Ramasamy K
Expert Opin Investig Drugs; 2011 May; 20(5):691-700. PubMed ID: 21413906
[TBL] [Abstract][Full Text] [Related]
46. Pomalidomide in the treatment of relapsed multiple myeloma.
Forsberg PA; Mark TM
Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
[TBL] [Abstract][Full Text] [Related]
47. Pomalidomide.
Engelhardt M; Wäsch R; Reinhardt H; Kleber M
Recent Results Cancer Res; 2014; 201():359-72. PubMed ID: 24756804
[TBL] [Abstract][Full Text] [Related]
48. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Mark TM; Coleman M; Niesvizky R
Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
[TBL] [Abstract][Full Text] [Related]
49. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Richardson PG; Mark TM; Lacy MQ
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
[TBL] [Abstract][Full Text] [Related]
50. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
51. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
52. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.
Sakamaki I; Kwak LW; Cha SC; Yi Q; Lerman B; Chen J; Surapaneni S; Bateman S; Qin H
Leukemia; 2014 Feb; 28(2):329-37. PubMed ID: 23765229
[TBL] [Abstract][Full Text] [Related]
53. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
54. Lenalidomide in multiple myeloma.
Kim Y; Schmidt-Wolf IG
Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
[TBL] [Abstract][Full Text] [Related]
55. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.
Yu T; Chaganty B; Lin L; Xing L; Ramakrishnan B; Wen K; Hsieh PA; Wollacott A; Viswanathan K; Adari H; Cho SF; Li Y; Chen H; Yang W; Xu Y; An G; Qiu L; Munshi N; Babcock G; Shriver Z; Myette JR; Anderson KC; Tai YT
Blood Cancer J; 2020 Nov; 10(11):110. PubMed ID: 33149123
[TBL] [Abstract][Full Text] [Related]
56. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Hideshima T; Cottini F; Ohguchi H; Jakubikova J; Gorgun G; Mimura N; Tai YT; Munshi NC; Richardson PG; Anderson KC
Blood Cancer J; 2015 May; 5(5):e312. PubMed ID: 25978432
[TBL] [Abstract][Full Text] [Related]
57. HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Won HR; Lee DH; Yeon SK; Ryu HW; Kim GW; Kwon SH
Int J Oncol; 2019 Aug; 55(2):499-512. PubMed ID: 31268156
[TBL] [Abstract][Full Text] [Related]
58. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
[TBL] [Abstract][Full Text] [Related]
59. The role of immunomodulatory drugs in multiple myeloma.
Anderson KC
Semin Hematol; 2003 Oct; 40(4 Suppl 4):23-32. PubMed ID: 15015893
[TBL] [Abstract][Full Text] [Related]
60. Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation.
Fostier K; Caers J; Meuleman N; Broos K; Corthals J; Thielemans K; Schots R; De Keersmaecker B
Oncotarget; 2018 Apr; 9(29):20476-20489. PubMed ID: 29755666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
